Clinical trials: Idarubicin
Acute Myeloblastic Leukaemia
Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
This protocol is a multicenter, national, open-label, single-arm, non-controlled study designed to establish the efficacy (in terms of response and survival) and safety of panobinostat in combination with idarubicin and…
- Trial name
- PANOBIDARA (NCT00840346)
- Testing
- panobinostat
- Where
- 9 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PETHEMA Foundation
Acute Promyelocytic Leukemia
Frontline Oral Arsenic Trioxide for APL
The investigators have formulated an oral preparation of arsenic trioxide (oral-ATO), and shown that it is efficacious for APL in R1, inducing CR2 in more than 90% of patients [8,9].
- Trial name
- NCT04687176
- Testing
- Oral Arsenic Trioxide Formulation
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
A Phase 3, randomized, open-label, parallel-group, multicenter study designed to evaluate the efficacy and safety of guadecitabine in participants with MDS or CMML who failed or relapsed after adequate prior treatment with…
- Trial name
- NCT02907359
- Testing
- Guadecitabine, Treatment Choice
- Where
- 112 sites in United States, Belgium and 12 more
- Volunteers
- 417 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Carcinoma, Hepatocellular Carcinoma
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study
To clarify the safety and efficacy of using uniform-sized drug-loaded embolic microspheres (E-TACE) of different particle sizes for graded embolization during TACE combined with Donafenib in the treatment of unresectable primary…
- Trial name
- NCT07180459
- Testing
- E-TACE, Donafenib
- Where
- 10 sites in China
- Volunteers
- 118 people
- Sponsor
- Xuhua Duan
Acute Myeloid Leukemia
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
The purpose of this study is to test the safety and determine the best dose of venetoclax and cytarabine when given with or without idarubicin in treating pediatric patients with acute myeloid leukemia (AML) that did not respond…
- Trial name
- NCT03194932
- Testing
- Venetoclax, Cytarabine, Idarubicin
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemias
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of revumenib in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML)…
- Trial name
- NCT06226571
- Testing
- Revumenib, Chemotherapy Regimen, HiDAC
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 96 people
- Sponsor
- Syndax Pharmaceuticals
AML (Acute Myelogenous Leukemia), Down Syndrome (DS)
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
This prospective non-randomized multicenter trial created based on protocol ML DS 2006 and aimed at standardization of current therapy approaches and creating a national network for diagnostic, treatment and monitoring of…
- Trial name
- AML-DS-2025 (NCT07232134)
- Testing
- 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Myeloid Leukemia
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment…
- Trial name
- NCT01035502
- Testing
- Elacytarabine plus idarubicin
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 51 people
- Sponsor
- Clavis Pharma
Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002565
- Testing
- bleomycin sulfate, CHOP regimen, cisplatin
- Where
- 3 sites in United States, Brazil and 1 more
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Promyelocytic Leukemia, Adult Acute
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all…
- Trial name
- NCT04897490
- Testing
- Evaluation of first line treatment with ATO/ATRA outcome
- Where
- 6 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Acute Myeloid Leukemia
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone.
- Trial name
- NCT03616470
- Testing
- Uproleselan
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 388 people
- Sponsor
- GlycoMimetics Incorporated
Primary Central Nervous System Lymphoma
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT02836158
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
Hepatic Cancer, Surgery
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT)…
- Trial name
- NCT06492408
- Testing
- ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Myelogenous Leukemia, Acute
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
This Phase 1/1b, open-label study will evaluate the safety and pharmacokinetics of escalating doses of RO5503781 as a single agent or in combination with cytarabine in participants with acute myelogenous leukemia.
- Trial name
- NCT01773408
- Testing
- RO5503781 MBP, RO5503781 SDP, Idarubicin
- Where
- 12 sites in United States, Australia and 5 more
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma
The purpose of this observational study is to evaluate properties of lipiodol-idarubicin emulsion mixed with the best regimen obtained in vitro study, including stability, viscosity，visibility under X-ray and deposition, in order…
- Trial name
- NCT05631613
- Testing
- cTACE(conventional transarterial chemoembolization)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongda Hospital
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
This randomized phase I trial is studying the side effects and best dose of vorinostat when given together with idarubicin in treating patients with relapsed or refractory leukemia or myelodysplastic syndromes.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00331513
- Testing
- vorinostat, idarubicin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Surgery
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
This phase II trial studies how well intra-tumor injection of double checkpoint inhibitors work when given alone and in combination with chemotherapy or/and bevacizumab in treating patients with previously untreated stage I-IIIA…
- Conditions
- Lung Cancer, Surgery, Non-small Cell Lung Cancer
- Trial name
- NCT06492421
- Testing
- ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Untreated Adult Acute Myeloid Leukemia
Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
This randomized phase II trial studies how well guadecitabine with or without idarubicin or cladribine works in treating older patients with previously untreated acute myeloid leukemia.
- Trial name
- NCT02096055
- Testing
- Cladribine, Guadecitabine, Idarubicin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
This phase Ib/II trial studies the side effects and best dose of pevonedistat and to see how well it works in combination with cytarabine and idarubicin in treating patients with acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT03330821
- Testing
- Cytarabine, Idarubicin, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Southern California
Leukemia
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00006122
- Testing
- cytarabine, etoposide, gemtuzumab ozogamicin
- Where
- 18 sites in Austria, Belgium and 5 more
- Volunteers
- 106 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC